Thromboembolic disease in COVID-19 patients: A brief narrative review

Journal of Intensive Care

Kunal Karamchandani¹  Somnath Bose²  Samhati Mondal³  Ashley L. Quintili⁴ 

[1] Department of Anesthesiology and Perioperative Medicine, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA;Department of Anesthesiology, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, One Deaconess Road, Rosenberg 470, 02215, Boston, MA, USA;Department of Anesthesiology, University of Maryland School of Medicine, Baltimore, MD, USA;Department of Pharmacy, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA;

关键词: COVID-19;    thrombosis;    thromboembolism;    SARS-CoV2;    management;    coagulation;   

DOI  :  10.1186/s40560-020-00483-y

来源: Springer

【 摘 要 】

Corona virus 2 (SARS-CoV2/ Severe Acute Respiratory Syndrome Corona Virus 2) infection has emerged as a global health crisis. Incidence of thromboembolic disease is reported to be high in SARS-CoV2 disease and is seen in a multitude of organ systems ranging from cutaneous thrombosis to pulmonary embolism, stroke or coronary thrombosis sometimes with catastrophic outcomes. Evidence points towards a key role of thromboembolism, hypercoagulability and over production of proinflammatory cytokines mimicking a “cytokine storm” which leads to multiorgan failure. This brief narrative review highlights the pathophysiology and risk factors of thromboembolic disease and provides a framework for management of anticoagulation based on the current evidence.

【 授权许可】

CC BY